ReviewNature methods2022
Challenges and opportunities for the next generation of cardiovascular tissue engineering.
Review in Nature methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 155 citations in OpenAlex.
- Differentiation of arterioles and capillaries in human blood vessel organoids with decellularized splenic matrix.Bioactive materials · 2026Article
- Spatially Resolved Photostimulation of Cardiac Activity Using Optoelectronic Peptides.ACS central science · 2026Article
- Digital Light Processing 3D Printing Enables Versatile Fabrication of Human Engineered Heart Tissues.Cell biomaterials · 2026Article
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- Biofabrication for spatial control of multiscale biological crosstalk in tissue models.npj biomedical innovations · 2026Review
- Clinical translation and engineering challenges of soft robotic cardiac sleeves for heart failure.Nature communications · 2026Review
- In vivo validation of multimodality pore-network modeling to identify angio-permissive scaffold porosity.Materials today. Bio · 2026Article
- Heart-on-a-chip and vasculature-on-a-chip platforms as models of cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Xeno-Free Peptide-Functionalized Hydrogels Support hiPSC Encapsulation andbioRxiv : the preprint server for biology · 2026Article
- A microphysiological system for screening lipid nanoparticle-mRNA complexes predicts in vivo heart transfection efficacy.Nature biomedical engineering · 2026Article
- Quantifying the spatiotemporal mechanical dynamics of engineered cardiac microbundles.PLoS computational biology · 2026Article
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Cardiac epigenome in heart development and disease.Nature reviews. Cardiology · 2026Review
- Advanced regenerative solutions in diabetic foot ulcer therapy: delivery of mesenchymal stem cells in injectable hydrogels.Stem cell research & therapy · 2026Review
- From chemically defined hiPSCs to self-organizing cardiac organoids: current strategies guided by developmental signaling.Stem cell research & therapy · 2026Review
- Advances and Challenges in Tissue Engineering: Biomaterials, Cellular Strategies, and Clinical Applications.Journal of functional biomaterials · 2026Review
- Bioprinting Organs-Science or Fiction?-A Review From Students to Students.Advanced healthcare materials · 2026Review
- Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell-Based Therapies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- The roles of the microtubule cytoskeletal network in cardiac mechanobiology.Journal of cell science · 2026Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Engineered cardiac tissues derived from human induced pluripotent stem cells offer unique opportunities for patient-specific disease modeling, drug discovery and cardiac repair. Since the first engineered hearts were introduced over two decades ago, human induced pluripotent stem cell-based three-dimensional cardiac organoids and heart-on-a-chip systems have now become mainstays in basic cardiovascular research as valuable platforms for investigating fundamental human pathophysiology and development. However, major obstacles remain to be addressed before the field can truly advance toward commercial and clinical translation. Here we provide a snapshot of the state-of-the-art methods in cardiac tissue engineering, with a focus on in vitro models of the human heart. Looking ahead, we discuss major challenges and opportunities in the field and suggest strategies for enabling broad acceptance of engineered cardiac tissues as models of cardiac pathophysiology and testbeds for the development of therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.